Another study of 320 high‐risk GIST samples prior to adjuvant imatinib treatment (of note, this research does not have analysis of KIT expression and KIT mutation status) found that 142 samples exhibited high expression of cyclin D1, with significantly increased cyclin D1 levels associated with higher mitotic counts (high risk GIST).53 This evidence concerns the gene KIT and gastrointestinal stromal tumor.